Human dCK C4S-S74E mutant in complex with UDP and the DI-43 inhibitor

Experimental Data Snapshot

  • Resolution: 1.94 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.

Murphy, J.M.Armijo, A.L.Nomme, J.Lee, C.H.Smith, Q.A.Li, Z.Campbell, D.O.Liao, H.I.Nathanson, D.A.Austin, W.R.Lee, J.T.Darvish, R.Wei, L.Wang, J.Su, Y.Damoiseaux, R.Sadeghi, S.Phelps, M.E.Herschman, H.R.Czernin, J.Alexandrova, A.N.Jung, M.E.Lavie, A.Radu, C.G.

(2013) J Med Chem 56: 6696-6708

  • DOI: https://doi.org/10.1021/jm400457y
  • Primary Citation of Related Structures:  
    4JLK, 4L5B

  • PubMed Abstract: 

    Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using (18)F-L-1-(2'-deoxy-2'-FluoroArabinofuranosyl) Cytosine ((18)F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = ∼1-12 nM) using the (18)F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy.

  • Organizational Affiliation

    Department of Molecular and Medical Pharmacology, §Ahmanson Translational Imaging Division, ⊥Department of Chemistry and Biochemistry, #California NanoSystems Institute, △Department of Biological Chemistry, University of California, Los Angeles , 650 Charles E. Young Dr. S., Los Angeles, California 90095, United States.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Deoxycytidine kinase
A, B
280Homo sapiensMutation(s): 5 
Gene Names: DCK
UniProt & NIH Common Fund Data Resources
Find proteins for P27707 (Homo sapiens)
Explore P27707 
Go to UniProtKB:  P27707
GTEx:  ENSG00000156136 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP27707
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on 1UX

Download Ideal Coordinates CCD File 
C [auth A],
E [auth B]
C22 H29 N5 O3 S2
Query on UDP

Download Ideal Coordinates CCD File 
D [auth A],
F [auth B]
C9 H14 N2 O12 P2
Binding Affinity Annotations 
IDSourceBinding Affinity
1UX BindingDB:  4L5B Ki: 0.8 (nM) from 1 assay(s)
IC50: min: 1.4, max: 15 (nM) from 2 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.94 Å
  • R-Value Free: 0.233 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 
  • Space Group: P 41
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 68.671α = 90
b = 68.671β = 90
c = 120.019γ = 90
Software Package:
Software NamePurpose
CrystalCleardata collection
XDSdata reduction
XDSdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2013-09-18
    Type: Initial release
  • Version 1.1: 2013-11-27
    Changes: Database references
  • Version 1.2: 2023-09-20
    Changes: Data collection, Database references, Derived calculations, Refinement description